← Back to Screener
Monopar Therapeutics Inc. Common Stock (MNPR)
Price$64.40
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-37.57%
Price vs S&P 500 (4W)17.17%
VGM Score66.86
Market Capitalization$435.71M
All Metrics
Book Value / Share (Quarterly)$20.21
P/TBV (Annual)0.46x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.49
Price vs S&P 500 (YTD)-11.33%
EPS (TTM)$-1.90
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-1.90
EPS (Annual)$-1.85
ROI (Annual)-9.95%
Cash / Share (Quarterly)$20.52
ROA (Last FY)-9.75%
EBITD / Share (TTM)$-2.40
ROE (5Y Avg)-68.19%
Cash Flow / Share (Annual)$-1.82
P/B Ratio3.22x
P/B Ratio (Quarterly)2.71x
Net Income / Employee (Annual)$-623,500
ROA (TTM)-12.57%
EPS Incl Extra (Annual)$-1.85
Current Ratio (Annual)51.35x
Quick Ratio (Quarterly)56.04x
3-Month Avg Trading Volume0.21M
52-Week Price Return100.80%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.47
52-Week High$105.00
EPS Excl Extra (Annual)$-1.85
Tangible BV CAGR (5Y)0.96%
26-Week Price Return-21.64%
Quick Ratio (Annual)51.35x
13-Week Price Return19.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)56.04x
Enterprise Value$383.16M
Book Value / Share Growth (5Y)71.95%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$20.98
3-Month Return Std Dev63.41%
Net Income / Employee (TTM)$-681,100
ROE (Last FY)-9.95%
EPS Basic Excl Extra (Annual)$-1.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.90
ROI (TTM)-12.84%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.78
Price vs S&P 500 (52W)72.60%
Year-to-Date Return-0.40%
5-Day Price Return3.04%
EPS Normalized (Annual)$-1.85
ROA (5Y Avg)-54.77%
Month-to-Date Return24.72%
Cash Flow / Share (TTM)$-0.40
EBITD / Share (Annual)$-2.25
ROI (5Y Avg)-68.19%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.90
P/TBV (Quarterly)0.69x
P/B Ratio (Annual)3.17x
Book Value / Share (Annual)$20.60
Price vs S&P 500 (13W)9.25%
Beta1.49x
Revenue / Share (TTM)$0.00
ROE (TTM)-12.84%
52-Week Low$28.40
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.46est. -0.85
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MNPRMonopar Therapeutics Inc. Common Stock | — | — | B | $64.40 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapeutics with a diversified pipeline spanning multiple development stages. The company's programs include Validive for chemoradiotherapy-induced oral mucositis in oropharyngeal cancer, camsirubicin for soft tissue sarcoma, the preclinical antibody MNPR-101 for cancers and severe COVID-19, and the early-stage analog MNPR-202 for multiple cancer types.